240 related articles for article (PubMed ID: 34589275)
61. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
[TBL] [Abstract][Full Text] [Related]
62.
Coffman SR; Lu J; Guo X; Zhong J; Jiang H; Broitman-Maduro G; Li WX; Lu R; Maduro M; Ding SW
mBio; 2017 Mar; 8(2):. PubMed ID: 28325765
[TBL] [Abstract][Full Text] [Related]
63. Silica nanoparticles and polyethyleneimine (PEI)-mediated functionalization: a new method of PEI covalent attachment for siRNA delivery applications.
Buchman YK; Lellouche E; Zigdon S; Bechor M; Michaeli S; Lellouche JP
Bioconjug Chem; 2013 Dec; 24(12):2076-87. PubMed ID: 24180511
[TBL] [Abstract][Full Text] [Related]
64. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
65. Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.
Gujrati M; Vaidya A; Lu ZR
Bioconjug Chem; 2016 Jan; 27(1):19-35. PubMed ID: 26629982
[TBL] [Abstract][Full Text] [Related]
66. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
67. Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells.
Xu X; Li L; Li X; Tao D; Zhang P; Gong J
Int J Pharm; 2020 Nov; 590():119963. PubMed ID: 33039492
[TBL] [Abstract][Full Text] [Related]
68. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer.
Ashrafizadeh M; Hushmandi K; Rahmani Moghadam E; Zarrin V; Hosseinzadeh Kashani S; Bokaie S; Najafi M; Tavakol S; Mohammadinejad R; Nabavi N; Hsieh CL; Zarepour A; Zare EN; Zarrabi A; Makvandi P
Bioengineering (Basel); 2020 Aug; 7(3):. PubMed ID: 32784981
[TBL] [Abstract][Full Text] [Related]
69. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.
Karim ME; Tha KK; Othman I; Borhan Uddin M; Chowdhury EH
Pharmaceutics; 2018 May; 10(2):. PubMed ID: 29861465
[TBL] [Abstract][Full Text] [Related]
70. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.
Sajid MI; Moazzam M; Kato S; Yeseom Cho K; Tiwari RK
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33036435
[TBL] [Abstract][Full Text] [Related]
71. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers.
Haque F; Shu D; Shu Y; Shlyakhtenko LS; Rychahou PG; Evers BM; Guo P
Nano Today; 2012 Aug; 7(4):245-257. PubMed ID: 23024702
[TBL] [Abstract][Full Text] [Related]
72. Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.
Deng K; Yang D; Zhou Y
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890239
[TBL] [Abstract][Full Text] [Related]
73. A fabricated siRNA nanoparticle for ultra-long gene silencing
Lee SK; Tung CH
Adv Funct Mater; 2013 Jul; 23(28):3488-3493. PubMed ID: 24999314
[TBL] [Abstract][Full Text] [Related]
74. Monitoring the
Sun L; Zhang J; Zhou JE; Wang J; Wang Z; Luo S; Wang Y; Zhu S; Yang F; Tang J; Lu W; Wang Y; Yu L; Yan Z
Asian J Pharm Sci; 2023 Jan; 18(1):100769. PubMed ID: 36698441
[TBL] [Abstract][Full Text] [Related]
75. Advancement of the Emerging Field of RNA Nanotechnology.
Jasinski D; Haque F; Binzel DW; Guo P
ACS Nano; 2017 Feb; 11(2):1142-1164. PubMed ID: 28045501
[TBL] [Abstract][Full Text] [Related]
76. Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment.
Hattab D; Gazzali AM; Bakhtiar A
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371702
[TBL] [Abstract][Full Text] [Related]
77. Artificial Base-Directed
Sun Y; Yu D; Geng X; Ding D; Yang Y; Liu Z; Xiao Z; Wang R; Tan W
ACS Appl Mater Interfaces; 2023 Feb; ():. PubMed ID: 36751121
[TBL] [Abstract][Full Text] [Related]
78. Dual-targeted lung cancer therapy
Han Y; Yang Y; Sun Q; Li B; Yue C; Liu Y; de la Fuente JM; Cui D
Cancer Biol Med; 2021 Aug; 19(7):1047-60. PubMed ID: 34427999
[TBL] [Abstract][Full Text] [Related]
79. Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases.
Kurakula H; Vaishnavi S; Sharif MY; Ellipilli S
ACS Omega; 2023 Jun; 8(23):20234-20250. PubMed ID: 37323391
[TBL] [Abstract][Full Text] [Related]
80. Programmable siRNA pro-drugs that activate RNAi activity in response to specific cellular RNA biomarkers.
Han SP; Scherer L; Gethers M; Salvador AM; Salah MBH; Mancusi R; Sagar S; Hu R; DeRogatis J; Kuo YH; Marcucci G; Das S; Rossi JJ; Goddard WA
Mol Ther Nucleic Acids; 2022 Mar; 27():797-809. PubMed ID: 35116191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
